TD Private Client Wealth’s Blueprint Medicines BPMC Stock Holding History

TD Private Client Wealth’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2	Closed	-$177	–	1423
2025 Q1	$177	Buy	+2	New	+$195	﹤0.01%	1382
2021 Q4	–	Sell	-6	Closed	-$617	–	1179
2021 Q3	$617	Hold	6	–	–	﹤0.01%	1148
2021 Q2	$528	Hold	6	–	–	﹤0.01%	1173
2021 Q1	$583	Hold	6	–	–	﹤0.01%	1112
2020 Q4	$673	Hold	6	–	–	﹤0.01%	1059
2020 Q3	$556	Hold	6	–	–	﹤0.01%	1025
2020 Q2	$468	Buy	+6	New	+$406	﹤0.01%	1030

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TD Private Client Wealth's BPMC Position: Q2 2025 in Review

TD Private Client Wealth sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 2 shares — an estimated $177 sold.

TD Private Client Wealth first reported a position in BPMC in Q2 2020 and held it in 7 quarters. The position peaked at $673 in Q4 2020. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

TD Private Client Wealth reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
TD Private Client Wealth sold 2 Blueprint Medicines shares in Q2 2025, an estimated $177.
TD Private Client Wealth first reported a position in Blueprint Medicines in Q2 2020 and held it in 7 quarters.
TD Private Client Wealth's Blueprint Medicines position peaked at $673 in Q4 2020.
354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on TD Private Client Wealth's 13F filing for Q2 2025, filed 15 Jul 2025.